Lexicon Confident in Sota HF Label After Entresto Approval; Lexicon Q4 and FY ’20 Earnings Update
Lexicon (press release) hosted its Q4 and FY ’20 earnings calls and provided updates to its diabetes business, including the company’s anticipated H2 ’21 sotagliflozin NDA filing for a heart failure indication. Recall, SOLOIST and SCORED positive results were first presented at AHA 2020 and published in the NEJM (SOLOIST-WHF publication and SCORED publication). Below, FENIX provides highlights and insights from the event.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.